Antibody Therapy for Acute Myeloid Leukemia

Seminars in Hematology

Volumn 45, Issue 2, 2008, Pages 104-109

  Mulford, Deborah ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD33 ANTIGEN; CD45 ANTIGEN; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; HUMAN; HYPERBILIRUBINEMIA; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION MOLECULES; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; TREATMENT OUTCOME;

EID: 41149107537     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.02.008     Document Type: Article

References (43)

1. Cassileth P.A., Harrington D.P., Appelbaum F.R., Lazarus H.M., Rowe J.M., Paietta E., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
2. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
3. Moore J.O., George S.L., Dodge R.K., Amrein P.C., Powell B.L., Kolitz J.E., et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood 105 (2005) 3420-3427
4. Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H., et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60 (1982) 454-462
5. Burnett A.K., Wheatley K., Goldstone A.H., Stevens R.F., Hann I.M., Rees J.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 118 (2002) 385-400
6. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., and Clark R.E. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1302-1311
7. Gardin C., Turlure P., Fagot T., Thomas X., Terre C., Contentin N., et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109 (2007) 5129-5135
8. Andrews R.G., Takahashi M., Segal G.M., Powell J.S., Bernstein I.D., and Singer J.W. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 68 (1986) 1030-1035
9. Legrand O., Perrot J.Y., Baudard M., Cordier A., Lautier R., Simonin G., et al. The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score. Blood 96 (2000) 870-877
10. Sabbath K.D., Ball E.D., Larcom P., Davis R.B., and Griffin J.D. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 75 (1985) 746-753
11. Scheinberg D.A., Lovett D., Divgi C.R., Graham M.C., Berman E., Pentlow K., et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9 (1991) 478-490
12. Caron P.C., Lai L.T., and Scheinberg D.A. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1 (1995) 63-70
13. Feldman E., Kalaycio M., Weiner G., Frankel S., Schulman P., Schwartzberg L., et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 17 (2003) 314-318
14. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., O'Connor J., et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23 (2005) 4110-4116
15. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85 (1995) 1122-1131
16. Matthews D.C., Appelbaum F.R., Eary J.F., Fisher D.R., Durack L.D., Hui T.E., et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94 (1999) 1237-1247
17. Ruffner K.L., and Matthews D.C. Current uses of monoclonal antibodies in the treatment of acute leukemia. Semin Oncol 27 (2000) 531-539
18. Bunjes D., Buchmann I., Duncker C., Seitz U., Kotzerke J., Wiesneth M., et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study. Blood 98 (2001) 565-572
19. Sievers E.L., Appelbaum F.R., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93 (1999) 3678-3684
20. Larson R.A., Sievers E.L., Stadtmauer E.A., Lowenberg B., Estey E.H., Dombret H., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 (2005) 1442-1452
21. Sievers E.L. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 1 (2001) 893-901
22. McKoy J.M., Angelotta C., Bennett C.L., Tallman M.S., Wadleigh M., Evens A.M., et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the Research on Adverse Drug Events and Reports (RADAR) project. Leuk Res 31 (2007) 599-604
23. Amadori S., Suciu S., Stasi R., Willemze R., Mandelli F., Selleslag D., et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 19 (2005) 1768-1773
24. Estey E.H., Thall P.F., Giles F.J., Wang X.M., Cortes J.E., Beran M., et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99 (2002) 4343-4349
25. Nabhan C., Rundhaugen L.M., Riley M.B., Rademaker A., Boehlke L., Jatoi M., et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 29 (2005) 53-57
26. Roboz G.J., Knovich M.A., Bayer R.L., Schuster M.W., Seiter K., Powell B.L., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 43 (2002) 1951-1955
27. Fianchi L., Pagano L., Leoni F., Storti S., Voso M.T., Valentini C.G., et al. Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol 19 (2008) 128-134
28. Piccaluga P.P., Martinelli G., Rondoni M., Malagola M., Gaitani S., Visani G., et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 28 (2004) 987-990
29. Stone R., Moser B., Schulman P., Barrier R., Kolitz J.E., Allen S., et al. A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients with refractory or relapsed acute myeloid leukemia (AML): CALGB19902. Blood 104 (2004) 249 (abstr)
30. Clavio M., Vignolo L., Albarello A., Varaldo R., Pierri I., Catania G., et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 138 (2007) 186-195
31. Alvarado Y., Tsimberidou A., Kantarjian H., Cortes J., Garcia-Manero G., Faderl S., et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51 (2003) 87-90
32. Cortes J., Tsimberidou A.M., Alvarez R., Thomas D., Beran M., Kantarjian H., et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50 (2002) 497-500
33. Linenberger M.L., Hong T., Flowers D., Sievers E.L., Gooley T.A., Bennett J.M., et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98 (2001) 988-994
34. Apostolidou E., Cortes J., Tsimberidou A., Estey E., Kantarjian H., and Giles F.J. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27 (2003) 887-891
35. + primary resistant or relapsed acute myeloid leukemia. Leuk Res 27 (2003) 893-897
36. Tsimberidou A., Estey E., Cortes J., Thomas D., Faderl S., Verstovsek S., et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97 (2003) 1481-1487
37. Kell W.J., Burnett A.K., Chopra R., Yin J.A., Clark R.E., Rohatiner A., et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 (2003) 4277-4283
38. De Angelo D., Schiffer C.A., and Stone R. Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients < 60 years old with untreated acute myeloid leukemia. Blood 100 (2002) 198-199 (abstr)
39. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
40. van der Velden V.H., Boeckx N., Jedema I., te Marvelde J.G., Hoogeveen P.G., Boogaerts M., et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18 (2004) 983-988
41. Lo-Coco F., Cimino G., Breccia M., Noguera N.I., Diverio D., Finolezzi E., et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104 (2004) 1995-1999
42. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107 (2006) 3469-3473
43. Estey E.H., Giles F.J., Beran M., O'Brien S., Pierce S.A., Faderl S.H., et al. Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99 (2002) 4222-4224